Table 1.
Patient demographics and baseline disease characteristics
| Characteristic | PBO (N = 230) | GMB 120 mg (N = 232) |
|---|---|---|
| Age, years, mean (SD) | 45.7 (12.3) | 45.9 (11.3) |
| Female, n (%) | 202 (87.8) | 195 (84.1) |
| Race (N = 223), n (%) | ||
| White | 182 (81.6) | 183 (81.7) |
| Asian | 35 (15.7) | 37 (16.5) |
| Black or African American | 2 (0.9) | 3 (1.3) |
| Duration of migraine illness, years, mean (SD) | 23.8 (13.9) | 22.7 (13.2) |
| Monthly migraine headache days, mean (SD) | 13.0 (5.7) | 13.4 (6.1) |
| Weekly migraine headache days,a mean (SD) | 3.0 (1.3) | 3.1 (1.4) |
| Total number of failed individual preventive medications in past 10 years,b mean (SD) | 3.3 (1.7) | 3.3 (1.6) |
PBO Placebo. GMB Galcanezumab. SD Standard deviation. N Number of intent-to-treat patients. n Number of patients within each specific category
aBased on baseline monthly migraine headache days and normalized to a weekly range
bBased on any medications taken for migraine prevention in the past 10 years; not limited to the qualifying standard-of care treatments specified in the inclusion criteria. Medication failure was defined as discontinuation due to no response, inadequate response, or safety/tolerability event. Contraindications did not count as medication failures